MmpL3 Inhibition as a Promising Approach to Develop Novel Therapies against Tuberculosis: A Spotlight on SQ109, Clinical Studies, and Patents Literature

Small molecules as kinetoplastid specific proteasome inhibitors for leishmaniasis: a patent review from 1998 to 2021

(2022) Mohd Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Development of Therapeutic and Prophylactic Zinc Compositions for Use against COVID-19: A Glimpse of the Trends, Inventions, and Patents

(2022) Mohd Imran et al.   Nutrients

The Therapeutic and Prophylactic Potential of Quercetin against COVID-19: An Outlook on the Clinical Studies, Inventive Compositions, and Patent Literature

(2022) Mohd Imran et al.   Antioxidants

An insight into the discovery, clinical studies, compositions, and patents of macozinone: A drug targeting the DprE1 enzyme of Mycobacterium tuberculosis

(2022) Mohd. Imran et al.   Journal of Infection and Public Health

Synthetic molecules as DprE1 inhibitors: A patent review

(2021) Mohd. Imran et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Mycobacterial Membrane Protein Large 3 (MmpL3) Inhibitors: A Promising Approach to Combat Tuberculosis

(2021) Mohit D. Umare et al.   ChemMedChem

Structures of the mycobacterial membrane protein MmpL3 reveal its mechanism of lipid transport

(2021) Chih-Chia Su et al.   PLOS BIOLOGY

Structure, In Vivo Detection, and Antibacterial Activity of Metabolites of SQ109, an Anti-Infective Drug Candidate

(2021) Satish R. Malwal et al.   ACS Infectious Diseases

Innovations and Patent Trends in the Development of USFDA Approved Protein Kinase Inhibitors in the Last Two Decades

(2021) Mohd. Imran et al.   Pharmaceuticals

Discovery, Development, Inventions, and Patent Trends on Mobocertinib Succinate: The First-in-Class Oral Treatment for NSCLC with EGFR Exon 20 Insertions

(2021) Mohd Imran et al.   Biomedicines

Mycobacterium tuberculosis Pathogenesis, Infection Prevention and Treatment

(2020) Riccardo Miggiano et al.   Pathogens

Targeting MmpL3 for anti-tuberculosis drug development

(2020) Jani R. Bolla   BIOCHEMICAL SOCIETY TRANSACTIONS

MmpL3 inhibitors as antituberculosis drugs

(2020) Min Shao et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation based on their Docking or Crystallographic Analyses against M. tuberculosis Enzyme Targets

(2020) Rishita Dey et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

MmpL3 Inhibition: A New Approach to Treat Nontuberculous Mycobacterial Infections

(2020) Jigar P. Sethiya et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Mycobacterial enzyme targets and their inhibitors

(2019) Anil Kumar Saxena et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

MmpL3 is a lipid transporter that binds trehalose monomycolate and phosphatidylethanolamine

(2019) Chih-Chia Su et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

An overview of new antitubercular drugs, drug candidates, and their targets

(2019) Aparna Bahuguna et al.   MEDICINAL RESEARCH REVIEWS

Drug discovery in tuberculosis. New drug targets and antimycobacterial agents

(2018) André Campaniço et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Laboratory diagnosis of tuberculosis: Advances in technology and drug susceptibility testing

(2017) Seema Oommen et al.   Indian Journal of Medical Microbiology

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

(2017) Martin J Boeree et al.   LANCET INFECTIOUS DISEASES

MmpL3 is the flippase for mycolic acids in mycobacteria

(2017) Zhujun Xu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

The Challenge of Latent TB Infection

(2016) Henry M. Blumberg et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Classification of drugs to treat multidrug-resistant tuberculosis (MDR-TB): evidence and perspectives

(2016) Adrian Rendon et al.   Journal of Thoracic Disease

Structure–Function Profile of MmpL3, the Essential Mycolic Acid Transporter from Mycobacterium tuberculosis

(2016) Juan Manuel Belardinelli et al.   ACS Infectious Diseases

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients

(2015) Norbert Heinrich et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Simultaneous staining of sputum smears for acid-fast and lipid-containing Myobacterium tuberculosis can enhance the clinical evaluation of antituberculosis treatments

(2015) Xavier A. Kayigire et al.   TUBERCULOSIS

Tuberculosis Vaccines and Prevention of Infection

(2014) Thomas R. Hawn et al.   MICROBIOLOGY AND MOLECULAR BIOLOGY REVIEWS

MmpL3 a potential new target for development of novel anti-tuberculosis drugs

(2013) Geetha Vani Rayasam   EXPERT OPINION ON THERAPEUTIC TARGETS

Discovery and development of SQ109: a new antitubercular drug with a novel mechanism of action

(2012) Katherine A Sacksteder et al.   Future Microbiology

Giving TB wheels: Public transportation as a risk factor for tuberculosis transmission

(2011) Marsha L. Feske et al.   TUBERCULOSIS

New drugs and regimens for treatment of TB

(2010) Eric Leibert et al.   Expert Review of Anti-Infective Therapy

SQ109

(2008)   TUBERCULOSIS